Fig. 1: Survival characteristics and prognostic factors in the glioblastoma population.
From: Medical comorbidities prognosticate survival in glioblastoma
Overall Survival (OS) of the entire cohort was 11 months (95% CI 10–12) (a). Younger age (b), high Karnofsky Performance Status (KPS) (c), gross total resection (d), and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation (e) are favorable prognostic factors. Patients treated with radiation and temozolomide (TMZ) (f), as well as those treated with bevacizumab (g), lived longer than those without.
